Efficacy and Safety of intravenous alteplase for unknown onset stroke on prior antiplatelet therapy: post-hoc analysis of the EOS Individual Participant Data.

Abstract

Background: The effects of intravenous alteplase in patients with prior antiplatelet therapy (APT) remain controversial. We aimed to assess the efficacy and safety of imaging-based intravenous alteplase in patients with unknown-onset stroke with prior APT.

Methods: Data from randomized controlled trials comparing alteplase with placebo/standard care in patients with unknown-onset acute ischemic stroke from the Evaluation of Unknown Onset Stroke Thrombolysis (EOS) individual patient data meta-analysis collaboration were analyzed. Favorable outcome was defined as a modified Rankin Scale score 0-1 at 90 d poststroke. Safety outcomes included symptomatic intracranial hemorrhage (sICH) at 22-36 h and 90-d mortality.

Results: Overall, 780 patients had available baseline data on prior APT. Compared with the no prior APT group (n=523), the prior APT group (n=257) was older (72 years vs. 66 years) and had a higher prevalence of vascular risk factors. There was no interaction between prior APT and treatment effects of alteplase (p for interaction=0.23). In the prior APT patients, 55/125 (45%) patients in the alteplase group and 39/132 (30%) patients in the control group had a favorable outcome (adjusted odds ratio [aOR], 2.07 [95% CI, 1.18-3.64]). The rates of sICH and mortality in the alteplase and control groups were 5.6% and 0.8%, respectively (aOR, 7.78 [0.94-63.37]) and 6.5% and 6.1%, respectively (aOR, 1.12 [0.38-3.36]). In the no prior APT patients, 136 patients (50%) in the alteplase group and 112 patients (45%) in the control group had a favorable outcome (aOR, 1.39 [0.94-2.05]). Safety outcomes were not significantly different between the groups (sICH: 3 [1.1%] vs. 1 [0.4%]; mortality: 13 [4.9%] vs. 3 [1.2%]).

Conclusions: Alteplase has consistent efficacy regardless of prior APT in patients with unknown-onset stroke. Additionally, prior APT does not significantly increase the risk of sICH or mortality.